Delamanid (OPC-67683) is an orally active mycolic acid biosynthesis inhibitor that is effective against both drug-susceptible and drug-resistant strains of M. tuberculosis H37Rv in vitro (MIC = 6 ng/mL) and exhibits significant in vivo efficacy with ~15-fold higher potency than rifampicin (RFP) in mice infected with M. tuberculosis Kurono (fold of lung CFU reduction post 28 days = 41.5 with 5 mg RFP/kg or 0.313 mg delamanid/kg daily orally dosage, 11,000-fold reduction with 0.625 mg delamanid/kg daily orally dosage).
Orally active mycolic acid biosynthesis inhibitor that is effective against drug-resistant strains of M. tuberculosis and is superior to rifampicin in vivo.
Journal of medicinal chemistry, 49(26), 7854-7860 (2006-12-22)
In an effort to develop potent new antituberculosis agents that would be effective against both drug-susceptible and drug-resistant strains of Mycobacterium tuberculosis, we prepared a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles substituted at the 2-position with various phenoxymethyl groups and
Tuberculosis (TB) is still a leading cause of death worldwide. Almost a third of the world's population is infected with TB bacilli, and each year approximately 8 million people develop active TB and 2 million die as a result. Today's
